Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Drugs
981-1,000 of 1,312 results
-
-
Looking For Lower Medicare Drug Costs? Ask Your Pharmacist For The Cash Price.
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
By Susan Jaffe -
Benefit Change Could Raise Costs For Patients Getting Drug Copay Assistance
More health plans are refusing to count the copayment assistance offered by drug makers as part of the patients’ deductibles or out-of-pocket limits.
-
Best Reads Of The Week With Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Podcast: KHN’s ‘What The Health?’ Campaign Promises Kept, Plus ‘Nerd Reports’
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Sarah Kliff of Vox and Alice Ollstein of Talking Points Memo discuss a proposed administration regulation that seeks to separate Planned Parenthood from federal family planning funds, the final congressional passage of legislation aimed at helping those with terminal illnesses obtain experimental medications, and new government reports on the uninsured and federal health spending. Also, Rovner interviews KHN’s Liz Szabo about the May “Bill of the Month.”
-
Pfizer Settles Kickback Case Related To Copay Assistance For $24M
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
-
Watch: What’s In The White House Plan To Lower Drug Prices
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ "Red & Blue."
-
Drugmakers Blamed For Blocking Generics Have Jacked Up Prices And Cost U.S. Billions
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
-
Best Reads Of The Week With Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Vermont Legislators Pass A Drug Importation Law. So What?
The first-in-the-nation measure would empower Vermont to set up a wholesale program to import prescription drugs from Canada. But it still will have to get federal buy-in before it is operational.
-
Podcast: KHN’s ‘What The Health?’ Much Ado About Drug Prices
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call discuss President Donald Trump’s proposals to control prescription drug prices and the efforts to sell the plan to lawmakers and the public. Also, Rovner interviews emeritus law professor Timothy Jost about the state of the Affordable Care Act.
-
Reversing An Overdose Isn’t Complicated, But Getting The Antidote Can Be
Last month, U.S. Surgeon General Jerome Adams urged more Americans to carry and learn to use naloxone, which can save someone from an opioid overdose. But the drug, brand-name Narcan, can be difficult to get and expensive.
-
Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
By Sarah Jane Tribble and Liz Szabo -
Best Reads Of The Week With Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Why Did Novartis Pay Trump’s Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
By Jay Hancock -
Podcast: KHN’s ‘What The Health?’ The Politics Of Rising Premiums And Menu Labeling
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times and Anna Edney of Bloomberg News discuss the latest on the politics of rising premiums, GOP efforts to take back money from the Children’s Health Insurance Program, and the controversy over new rules requiring calorie information on menus. Plus for extra credit, the panelists recommend their favorite health stories of the week.
-
Midterm Elections Are Shaping Up To Be A Referendum On Trumpism
Even voters who say they are more enthusiastic about voting in this congressional election than in past ones are not motivated by any specific issue. But, according to a poll out Thursday, health care policies rank high among topics voters want candidates to address.
By Rachel Bluth -
Use Of Psychiatric Drugs Soars In California Jails
A combination of factors has led to an “astronomical” increase in mentally ill inmates, followed by increased efforts to identify those who need prescriptions. Some say the meds are underprescribed; others, that they are given inappropriately, without the benefit of comprehensive treatment.
By Anna Gorman -
‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.
-
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
By Jay Hancock and Elizabeth Lucas